Oric Pharmaceuticals, Inc. $ORIC Shares Sold by EcoR1 Capital LLC

EcoR1 Capital LLC decreased its position in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 52.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,618,068 shares of the company’s stock after selling 1,800,000 shares during the quarter. Oric Pharmaceuticals accounts for approximately 1.0% of EcoR1 Capital LLC’s portfolio, making the stock its 21st largest holding. EcoR1 Capital LLC owned 1.67% of Oric Pharmaceuticals worth $16,423,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ORIC. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Oric Pharmaceuticals by 2.9% during the second quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 49,000 shares of the company’s stock worth $497,000 after buying an additional 1,358 shares in the last quarter. ANTIPODES PARTNERS Ltd raised its position in shares of Oric Pharmaceuticals by 35.9% in the second quarter. ANTIPODES PARTNERS Ltd now owns 5,194 shares of the company’s stock worth $53,000 after acquiring an additional 1,372 shares during the period. Nisa Investment Advisors LLC boosted its stake in shares of Oric Pharmaceuticals by 17,300.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company’s stock worth $25,000 after acquiring an additional 2,422 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Oric Pharmaceuticals by 7.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 38,864 shares of the company’s stock valued at $394,000 after acquiring an additional 2,706 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Oric Pharmaceuticals by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company’s stock valued at $226,000 after acquiring an additional 3,131 shares during the period. 95.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Jacob Chacko sold 125,000 shares of the stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $10.80, for a total value of $1,350,000.00. Following the completion of the sale, the chief executive officer owned 656,419 shares of the company’s stock, valued at approximately $7,089,325.20. This trade represents a 16.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Dominic Piscitelli sold 11,000 shares of the business’s stock in a transaction on Monday, October 6th. The stock was sold at an average price of $14.52, for a total value of $159,720.00. Following the transaction, the chief financial officer directly owned 48,317 shares in the company, valued at $701,562.84. This trade represents a 18.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 261,000 shares of company stock worth $3,024,703 over the last three months. Corporate insiders own 6.82% of the company’s stock.

Wall Street Analyst Weigh In

ORIC has been the topic of a number of recent analyst reports. Oppenheimer increased their price target on Oric Pharmaceuticals from $12.00 to $15.00 and gave the stock an “outperform” rating in a research report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Wednesday, October 8th. Wolfe Research began coverage on shares of Oric Pharmaceuticals in a research note on Tuesday, November 18th. They issued a “peer perform” rating on the stock. Wells Fargo & Company boosted their price target on shares of Oric Pharmaceuticals from $19.00 to $25.00 and gave the stock an “overweight” rating in a report on Monday. Finally, JPMorgan Chase & Co. increased their price objective on shares of Oric Pharmaceuticals from $17.00 to $20.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Oric Pharmaceuticals Stock Down 3.2%

Shares of ORIC opened at $9.38 on Friday. Oric Pharmaceuticals, Inc. has a 52-week low of $3.90 and a 52-week high of $14.93. The stock has a market cap of $913.51 million, a PE ratio of -5.42 and a beta of 1.32. The firm’s fifty day moving average is $12.27 and its two-hundred day moving average is $10.91.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.08. As a group, research analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.